niacinamide and Cognition Disorders

niacinamide has been researched along with Cognition Disorders in 17 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research

Studies (17)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Activities of Daily Living - Mild Cognitive Impairment

The ADCS-ADL-MCI is a measure of patient functional performance in Alzheimer's Disease and Mild Cognitive Impairment trials. The informant-based questionnaire assesses conduct of basic and instrumental Activities of Daily Living (ADLs). A total of 24 ADLs are evaluated. Scores range from 0 to 53, with higher scores representing more maintained function. (NCT03061474)
Timeframe: Baseline to 48 weeks

ADASCog-13

ADAS-Cog13 is a structured scale that evaluates memory (immediate and delayed word recall; immediate word recognition), receptive and expressive language, orientation, ideational praxis (preparing a letter for mailing), constructional praxis (copying figures), and attention (number cancellation). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions also are obtained. Range: 0-85; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

CDR Sum of Boxes

CDR-SB is a composite rating of cognition and everyday function which incorporates both informant input and direct assessment of performance. It assesses through semi-structured interview three cognitive domains (memory, orientation, and judgement/problem solving) and three everyday functional domains (community affairs, home and hobbies, personal care). Level of impairment in each of the six domains is rated from none (score=0) to severe (score=3). The six domain scores are then summed to create the CDR-SB. Range 0-18; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in ab40

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab40 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in ab42

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab42 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in P-tau 181

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher total value is associated with greater severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in P-tau 231

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher phosphorylated tau (p-tau) is associated with a severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in QTC

Average within-subject change in electrocardiogram QT interval. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Ratio of Total Tau/ab40

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab40/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Ratio of Total Tau/ab42

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab42/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Change in Total Tau

Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD. (NCT03061474)
Timeframe: Baseline to 48 weeks

Count of Treatment Emergent Adverse Events

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

ECG Abnormalities

Count of participants experiencing at least one electrocardiogram (ECG) abnormality. (NCT03061474)
Timeframe: Baseline to 48 weeks

QTC Abnormalities

Count of participants experiencing at least one electrocardiogram (ECG) QT interval abnormality. Abnormal defined as above 460 for men and above 470 for women. (NCT03061474)
Timeframe: Baseline to 48 weeks

Columbia-Suicide Severity Rating Scale

"The Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the corresponding assessment period. The scale includes suggested questions to elicit the type of information needed to determine if a suicide-related thought or behavior occurred. The number and proportion of subjects with treatment emergent Suicidal ideation or behavior during the study period of (baseline to week 48) will be reported overall and by study arm. Treatment emergent suicidal ideation or behavior is defined as a yes answer at any time during treatment to any one of the questions in the ten suicidal ideation and behavior categories (Categories 1- 10) on the C-SSRS. Self-injurious behavior without suicidal intent, while assessed on the C-SSRS, does not form part of this outcome." (NCT03061474)
Timeframe: Baseline to 48 weeks

Count of Adverse Events by Severity

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

Vital Signs - BMI

Body Mass Index (BMI) was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Diastolic Blood Pressure

Diastolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Pulse

Pulse rate was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Systolic Blood Pressure

Systolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Vital Signs - Weight

Weight in kg was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

Trials

4 trials available for niacinamide and Cognition Disorders

Other Studies

13 other studies available for niacinamide and Cognition Disorders